Jump to content

Guaifenesin: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→top: Added Legal Status for NZ
Tags: Mobile edit Mobile app edit Android app edit
consistent citation formatting
(8 intermediate revisions by 7 users not shown)
Line 4: Line 4:
{{Drugbox
{{Drugbox
| verifiedrevid = 458631122
| verifiedrevid = 458631122
| class = [[Expectorant]]
| image = Guaifenesin.svg
| image = Guaifenesin.svg
| image2 = Guaifenesin molecule spacefill.png
| image2 = Guaifenesin molecule spacefill.png
Line 9: Line 10:
| chirality = [[Racemic mixture]]
| chirality = [[Racemic mixture]]


⚫
<!-- Clinical data -->| pronounce = {{IPAc-en|ɡ|w|aɪ|ˈ|f|ɛ|n|ᵻ|s|ɪ|n}}<ref>{{cite web| url = https://www.merriam-webster.com/medical/guaifenesin | access-date = | title = Guaifenesin Definition & Meaning|work = Merriam-Webster}}</ref>
<!-- Clinical data -->
⚫
| pronounce = {{IPAc-en|ɡ|w|aɪ|ˈ|f|ɛ|n|ᵻ|s|ɪ|n}}<ref>{{cite web| url = https://www.merriam-webster.com/medical/guaifenesin | access-date = | title = Guaifenesin Definition & Meaning|work = Merriam-Webster}}</ref>
| tradename = Mucinex, others
| tradename = Mucinex, others
| Drugs.com = {{drugs.com|monograph|guaifenesin}}
| Drugs.com = {{drugs.com|monograph|guaifenesin}}
Line 19: Line 19:
| ATC_suffix = CA03
| ATC_suffix = CA03
| ATC_supplemental = {{ATCvet|M03|BX90}}
| ATC_supplemental = {{ATCvet|M03|BX90}}

| legal_NZ = OTC
| legal_NZ = OTC
| legal_US = OTC
| legal_US = OTC
| legal_US_comment = /&nbsp;Rx-only
| legal_US_comment = /&nbsp;Rx-only


<!-- Pharmacokinetic data -->
<!-- Pharmacokinetic data -->| bioavailability =
| bioavailability =
| protein_bound =
| protein_bound =
| metabolism = [[Kidney]]
| metabolism = [[Kidney]]
| metabolites =
| metabolites =
| elimination_half-life = 1–5 hours<ref name="pmid8218524">{{cite journal|vauthors=Aluri JB, Stavchansky S | title=Determination of guaifenesin in human plasma by liquid chromatography in the presence of pseudoephedrine | journal=J Pharm Biomed Anal | year= 1993 | volume= 11 | issue= 9 | pages= 803–808 | pmid=8218524 | doi= 10.1016/0731-7085(93)80072-9}}</ref>
| elimination_half-life = 1–5 hours<ref name="pmid8218524">{{cite journal|vauthors=Aluri JB, Stavchansky S | title=Determination of guaifenesin in human plasma by liquid chromatography in the presence of pseudoephedrine | journal=J Pharm Biomed Anal | year= 1993 | volume= 11 | issue= 9 | pages= 803–808 | pmid=8218524 | doi= 10.1016/0731-7085(93)80072-9}}</ref>
| excretion =
| excretion = <!-- Identifiers -->

<!-- Identifiers -->
| IUPHAR_ligand = 7617
| IUPHAR_ligand = 7617
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number_Ref = {{cascite|correct|??}}
Line 49: Line 45:
| synonyms = Glyceryl guaiacolate
| synonyms = Glyceryl guaiacolate


<!-- Chemical data -->
<!-- Chemical data -->| IUPAC_name = (''RS'')-3-(2-methoxyphenoxy)propane-1,2-diol
| C = 10
| IUPAC_name = (''RS'')-3-(2-methoxyphenoxy)propane-1,2-diol
| C=10 | H=14 | O=4
| H = 14
| O = 4
| SMILES = O(c1ccccc1OC)CC(O)CO
| SMILES = O(c1ccccc1OC)CC(O)CO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
Line 60: Line 57:


<!-- Definition and medical uses -->
<!-- Definition and medical uses -->
'''Guaifenesin''', also known as '''glyceryl guaiacolate''', is an [[Mucoactive agent|expectorant]] [[medication]] taken by mouth and marketed as an aid to eliminate [[sputum]] from the [[respiratory tract]]. Chemically, it is an [[ether]] of [[guaiacol]] and [[Glycerol|glycerine]]. It may be used in combination with other medications.<ref name="drugs">{{cite web|title=Guaifenesin: Monograph for Professionals|url=https://www.drugs.com/monograph/guaifenesin.html|publisher=Drugs.com, American Society of Health-System Pharmacists|date=23 January 2023|access-date=30 July 2023}}</ref> A 2014 study found that guaifenesin has no effect on sputum production or clearance in upper respiratory infections (the upper respiratory system includes most breathing parts ''above'' the lungs).<ref name="pmid24003241">{{cite journal | vauthors = Hoffer-Schaefer A, Rozycki HJ, Yopp MA, Rubin BK | title = Guaifenesin has no effect on sputum volume or sputum properties in adolescents and adults with acute respiratory tract infections | journal = Respiratory Care | volume = 59 | issue = 5 | pages = 631–636 | date = May 2014 | pmid = 24003241 | doi = 10.4187/respcare.02640 | doi-access = free }}</ref><ref name="pmid24789023">{{cite journal | vauthors = O'Connell OJ | title = Is extended-release guaifenesin no better than a placebo? | journal = Respir Care | volume = 59 | issue = 5 | pages = 788–9 | date = May 2014 | pmid = 24789023 | doi = 10.4187/respcare.03319 | url = }}</ref>
'''Guaifenesin''', also known as '''glyceryl guaiacolate''', is an [[Mucoactive agent|expectorant]] medication taken by mouth and marketed as an aid to eliminate [[sputum]] from the [[respiratory tract]]. Chemically, it is an [[ether]] of [[guaiacol]] and [[Glycerol|glycerine]]. It may be used in combination with other medications.<ref name="drugs">{{cite web|title=Guaifenesin: Monograph for Professionals|url=https://www.drugs.com/monograph/guaifenesin.html|publisher=Drugs.com, American Society of Health-System Pharmacists|date=23 January 2023|access-date=30 July 2023}}</ref> A 2014 study found that guaifenesin does not affect sputum volume in upper respiratory infections (the upper respiratory system includes most breathing parts ''above'' the lungs).<ref name="pmid24003241">{{cite journal | vauthors = Hoffer-Schaefer A, Rozycki HJ, Yopp MA, Rubin BK | title = Guaifenesin has no effect on sputum volume or sputum properties in adolescents and adults with acute respiratory tract infections | journal = Respiratory Care | volume = 59 | issue = 5 | pages = 631–636 | date = May 2014 | pmid = 24003241 | doi = 10.4187/respcare.02640 | doi-access = free }}</ref><ref name="pmid24789023">{{cite journal | vauthors = O'Connell OJ | title = Is extended-release guaifenesin no better than a placebo? | journal = Respir Care | volume = 59 | issue = 5 | pages = 788–9 | date = May 2014 | pmid = 24789023 | doi = 10.4187/respcare.03319 | url = }}</ref>


<!-- Side effects and mechanism -->
<!-- Side effects and mechanism -->
Side effects may include dizziness, sleepiness, skin rash, and nausea.<ref name=drugs/> While it has not been properly studied in pregnancy, it appears to be safe.<ref name=Wei2013>{{cite book | vauthors = Weiner CP, Rope K |title=The Complete Guide to Medications During Pregnancy and Breastfeeding: Everything You Need to Know to Make the Best Choices for You and Your Baby |date=2013 |publisher=St. Martin's Press |isbn=9781250037206 |page=PT282 |url=https://archive.org/details/completeguidetom0000wein_t9k5 |url-access=registration |language=en}}</ref> It is believed to work by making airway secretions more liquid.<ref name=drugs/>
Side effects may include [[dizziness]], [[sleepiness]], [[skin rash]], and [[nausea]].<ref name=drugs/> While it has not been properly studied in pregnancy, it appears to be safe.<ref name=Wei2013>{{cite book | vauthors = Weiner CP, Rope K |title=The Complete Guide to Medications During Pregnancy and Breastfeeding: Everything You Need to Know to Make the Best Choices for You and Your Baby |date=2013 |publisher=St. Martin's Press |isbn=9781250037206 |page=PT282 |url=https://archive.org/details/completeguidetom0000wein_t9k5 |url-access=registration |language=en}}</ref> It is believed to work by making airway secretions more liquid.<ref name=drugs/>


<!-- History and culture -->
<!-- History and culture -->
Guaifenesin has been used medically since at least 1933.<ref>{{cite book | vauthors = Riviere JE, Papich MG |title=Veterinary Pharmacology and Therapeutics |date=2013 |publisher=John Wiley & Sons |isbn=9781118685907 |page=287 |url=https://books.google.com/books?id=xAPa4WDzAnQC&pg=PA287 }}</ref> It is available as a [[generic medication]] and [[Over-the-counter drug|over the counter]].<ref name=drugs/><ref name=Wei2013/> In 2021, it was the 288th most commonly prescribed medication in the United States, with more than 600,000 prescriptions.<ref>{{cite web | title=The Top 300 of 2021 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=14 January 2024 | archive-date=15 January 2024 | archive-url=https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Guaifenesin – Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Guaifenesin | access-date = 14 January 2024}}</ref>
Guaifenesin has been used medically since at least 1933.<ref>{{cite book | vauthors = Riviere JE, Papich MG |title=Veterinary Pharmacology and Therapeutics |date=2013 |publisher=John Wiley & Sons |isbn=9781118685907 |page=287 |url=https://books.google.com/books?id=xAPa4WDzAnQC&pg=PA287 }}</ref> It is available as a [[generic medication]] and [[Over-the-counter drug|over-the-counter]] (OTC).<ref name=drugs/><ref name=Wei2013/> In 2021, it was the 288th most commonly prescribed medication in the United States, with more than 600,000 prescriptions.<ref>{{cite web | title=The Top 300 of 2021 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=14 January 2024 | archive-date=15 January 2024 | archive-url=https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Guaifenesin – Drug Usage Statistics | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Guaifenesin | access-date = 14 January 2024}}</ref>


==Medical use==
==Medical uses==
Guaifenesin is used to try to help with coughing up thick mucus, and is sometimes combined with the [[antitussive]] (cough suppressant) [[dextromethorphan]], such as in Mucinex DM or Robitussin DM.<ref>{{cite web |url=http://www.webmd.com/drugs/mono-704-GUAIFENESIN%2fDEXTROMETHORPHAN+-+ORAL.aspx?drugid=5508&drugname=Guaifenesin+DM+Oral&source=0 |title=Guaifenesin DM |publisher=WebMD.com }}</ref> It is also combined with [[ephedrine]] in Primatene and Bronkaid tablets for symptomatic relief of [[asthma]]. Guaifenesin is combined with [[phenylephrine]] and [[paracetamol]] in certain [[Lemsip]] formulations.<ref>{{Cite web |title=Lemsip Max All in One |url=https://www.lemsip.co.uk/collections/lemsip-max-all-in-one |access-date=2024-11-04 |website=LemsipUK |language=en}}</ref>
Guaifenesin is used to try to help with coughing up thick mucus. It is sometimes combined with the [[antitussive]] (cough suppressant) [[dextromethorphan]], such as in Mucinex DM or Robitussin DM.<ref>{{cite web |url=http://www.webmd.com/drugs/mono-704-GUAIFENESIN%2fDEXTROMETHORPHAN+-+ORAL.aspx?drugid=5508&drugname=Guaifenesin+DM+Oral&source=0 |title=Guaifenesin DM |publisher=WebMD.com }}</ref> It is also combined with [[ephedrine]] in Primatene and Bronkaid tablets for symptomatic relief of [[asthma]]. Guaifenesin is combined with [[phenylephrine]] and [[paracetamol]] in certain [[Lemsip]] formulations.<ref>{{Cite web |title=Lemsip Max All in One |url=https://www.lemsip.co.uk/collections/lemsip-max-all-in-one |access-date=2024-11-04 |website=LemsipUK |language=en}}</ref>


A [[Cochrane review]] identified three [[clinical trial]]s assessing guaifenesin for the treatment of acute cough, with one finding significant benefit and the other two trials finding that it was not effective.<ref name="pmid25420096">{{cite journal | vauthors = Smith SM, Schroeder K, Fahey T | title = Over-the-counter (OTC) medications for acute cough in children and adults in community settings | journal = Cochrane Database Syst Rev | volume = 2014 | issue = 11 | pages = CD001831 | date = November 2014 | pmid = 25420096 | pmc = 7061814 | doi = 10.1002/14651858.CD001831.pub5 | url = }}</ref>
A [[Cochrane review]] identified three [[clinical trial]]s assessing guaifenesin for the treatment of acute cough, with one finding significant benefit and the other two trials finding that it was not effective.<ref name="pmid25420096">{{cite journal | vauthors = Smith SM, Schroeder K, Fahey T | title = Over-the-counter (OTC) medications for acute cough in children and adults in community settings | journal = Cochrane Database Syst Rev | volume = 2014 | issue = 11 | pages = CD001831 | date = November 2014 | pmid = 25420096 | pmc = 7061814 | doi = 10.1002/14651858.CD001831.pub5 | url = }}</ref>


==Side effects==
==Side effects==
Although generally well-tolerated, [[side-effect]]s of guaifenesin may include an [[allergic reaction]] (rare), [[nausea]], [[vomiting]], dizziness, or headache.<ref name="drugs-se">{{cite web |title=Guaifenesin Side Effects |url=https://www.drugs.com/sfx/guaifenesin-side-effects.html |publisher=Drugs.com |access-date=30 July 2023 |date=3 July 2023}}</ref><ref name=nlm>{{cite web | title = Guaifenesin | url = https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682494.html |publisher = MedlinePlus, United States National Library of Medicine|date=15 January 2022|accessdate=30 July 2023}}</ref>
Although generally well-tolerated, side effects of guaifenesin may include an [[allergic reaction]] (rare), [[nausea]], [[vomiting]], [[dizziness]], or [[headache]].<ref name="drugs-se">{{cite web |title=Guaifenesin Side Effects |url=https://www.drugs.com/sfx/guaifenesin-side-effects.html |publisher=Drugs.com |access-date=30 July 2023 |date=3 July 2023}}</ref><ref name=nlm>{{cite web | title = Guaifenesin | url = https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682494.html |publisher = MedlinePlus, United States National Library of Medicine|date=15 January 2022|accessdate=30 July 2023}}</ref>


==Pharmacology==
==Pharmacology==


===Mechanism of action===
===Mechanism of action===
Guaifenesin might act as an expectorant by increasing the volume and reducing the viscosity of secretions in the [[trachea]] and [[Bronchus|bronchi]] via stimulation of the gastric mucosa. This stimulation leads to an increased parasympathetic activity in the respiratory tract via the so-called gastro-pulmonary reflex, although some in vitro studies suggested that it might also act directly on the respiratory epithelium.<ref>{{cite journal | vauthors = Albrecht HH, Dicpinigaitis PV, Guenin EP | title = Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections | journal = Multidisciplinary Respiratory Medicine | volume = 12 | issue = 1 | pages = 31 | date = 2017-12-11 | pmid = 29238574 | pmc = 5724298 | doi = 10.1186/s40248-017-0113-4 | doi-access = free }}</ref> This increase in volume and reduction in viscosity aids in the flow of respiratory tract secretions, allowing ciliary movement to carry the loosened secretions upward toward the [[pharynx]].<ref name="e824">{{cite book | vauthors = Gutierrez K | title=Pharmacotherapeutics: clinical reasoning in primary care | publisher=Saunders Elsevier | publication-place=St. Louis, Mo | date=2007 | isbn=978-1-4160-3287-8 | page=}}</ref><ref>{{cite journal | vauthors = Ohar JA, Donohue JF, Spangenthal S | title = The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review | language = en-US | journal = Chronic Obstructive Pulmonary Diseases | volume = 6 | issue = 4 | pages = 341–349 | date = October 2019 | pmid = 31647856 | url = https://journal.copdfoundation.org/jcopdf/id/1248/The-Role-of-Guaifenesin-in-the-Management-of-Chronic-Mucus-Hypersecretion-Associated-with-Stable-Chronic-Bronchitis-A-Comprehensive-Review }}</ref>Thus, guaifenesin may increase the efficiency of the [[cough reflex]] and facilitate the removal of the secretions. Additionally, guaifenesin has a demonstrated central antitussive effect.<ref>{{cite journal | vauthors = Ohar JA, Donohue JF, Spangenthal S | title = The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review | language = en-US | journal = Chronic Obstructive Pulmonary Diseases | volume = 6 | issue = 4 | pages = 341–349 | date = October 2019 | pmid = 31647856 | url = https://journal.copdfoundation.org/jcopdf/id/1248/The-Role-of-Guaifenesin-in-the-Management-of-Chronic-Mucus-Hypersecretion-Associated-with-Stable-Chronic-Bronchitis-A-Comprehensive-Review }}</ref>
Guaifenesin is thought to act as an expectorant by increasing the volume and reducing the viscosity of secretions in the [[trachea]] and [[Bronchus|bronchi]]. It may aid in the flow of respiratory tract secretions, allowing ciliary movement to carry the loosened secretions upward toward the [[pharynx]].<ref>Gutierrez, K. (2007). Pharmacotherapeutics: Clinical Reasoning in Primary Care. W.B. Saunders Co.</ref> Thus, it may increase the efficiency of the [[cough reflex]] and facilitate removal of the secretions.


==History==
==History==
Similar medicines derived from the [[guaiacum|guaiac tree]] were in use as a generic remedy by American indigenous peoples when explorers reached [[North America]] in the 16th century. The Spanish encountered guaiacum wood "when they conquered [[Hispaniola|Santo Domingo]]; it was soon brought back to Europe, where it acquired an immense reputation in the sixteenth century as a cure for syphilis and certain other diseases..."<ref name="Wallis1955">{{cite book | vauthors = Wallis TE |title=Textbook of Pharmacognosy|url=https://archive.org/details/textbookofpharma00wall |url-access=registration |year=1955}}</ref>
Similar medicines derived from the [[guaiacum|guaiac tree]] were used as a generic remedy by American indigenous peoples when explorers reached [[North America]] in the 16th century. The Spanish encountered guaiacum wood "when they conquered [[Hispaniola|Santo Domingo]]; it was soon brought back to Europe, where it acquired an immense reputation in the sixteenth century as a cure for syphilis and certain other diseases..."<ref name="Wallis1955">{{cite book | vauthors = Wallis TE |title=Textbook of Pharmacognosy|url=https://archive.org/details/textbookofpharma00wall |url-access=registration |year=1955}}</ref>


The 1955 edition of the ''Textbook of [[Pharmacognosy]]'' states: "Guaiacum has a local stimulant action which is sometimes useful in sore throat. The resin is used in chronic gout and rheumatism, whilst the wood is an ingredient in the compound concentrated solution of [[Sarsaparilla (soft drink)|sarsaparilla]], which was formerly much used as an alternative in syphilis."<ref name="Wallis1955" />
The 1955 edition of the ''Textbook of [[Pharmacognosy]]'' states: "Guaiacum has a local stimulant action which is sometimes useful in sore throat. The resin is used in chronic gout and rheumatism, whilst the wood is an ingredient in the compound concentrated solution of [[Sarsaparilla (soft drink)|sarsaparilla]], which was formerly much used as an alternative in syphilis."<ref name="Wallis1955" />


In the US, guaifenesin was first approved by the [[Food and Drug Administration]] (FDA) in 1952. Although previously deemed "[[Generally Regarded as Safe]]" in its original approval, the drug received a [[New Drug Application]] for the extended-release version, which received approval on 12 July 2002.<ref>{{cite web | title=Drug Approval Package: Mucinex (Guaifenesin) NDA #21-282 | website=accessdata.fda.gov | date=25 November 2002 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-282_Mucinex.cfm | access-date=26 October 2022}}</ref> Because of this, the FDA then issued letters to other manufacturers of ''timed-release'' guaifenesin to stop marketing their unapproved versions, leaving Adams Respiratory Therapeutics in control of the market. In 2007, Adams was acquired by [[Reckitt Benckiser]].<ref>{{cite web |url=http://www.rb.com/site/RKBR/Templates/MediaInvestorsGeneral2.aspx?pageid=262&cc=GB |title=Announcements RB Press release - 10/12/2007 |access-date=16 November 2010 |archive-url=https://web.archive.org/web/20110715161154/http://www.rb.com/site/RKBR/Templates/MediaInvestorsGeneral2.aspx?pageid=262&cc=GB |archive-date=15 July 2011 |url-status=dead }}</ref><ref>{{cite news | vauthors = Goldstein J |title=FDA Bumps Phlegm-Fighters From Market |url=https://blogs.wsj.com/health/2007/05/25/fda-bumps-phlegm-fighters-from-market/ |date=25 May 2007 |newspaper=The Wall Street Journal |access-date=16 November 2010}}</ref> The drug is now sold over-the-counter by many companies, alone and in combination.<ref>{{Cite web|title=Guaifenesin (Oral Route) Description and Brand Names |url=https://www.mayoclinic.org/drugs-supplements/guaifenesin-oral-route/description/drg-20068720|access-date=27 July 2021|website=Mayo Clinic }}</ref>
In the US, guaifenesin was first approved by the [[Food and Drug Administration]] (FDA) in 1952. Although previously deemed "[[Generally Regarded as Safe]]" in its original approval, the drug received a [[New Drug Application]] for the extended-release version, which received approval on 12 July 2002.<ref>{{cite web | title=Drug Approval Package: Mucinex (Guaifenesin) NDA #21-282 | website=accessdata.fda.gov | date=25 November 2002 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-282_Mucinex.cfm | access-date=26 October 2022}}</ref> Because of this, the FDA then issued letters to other manufacturers of ''timed-release'' guaifenesin to stop marketing their unapproved versions, leaving Adams Respiratory Therapeutics in control of the market. In 2007, Adams was acquired by [[Reckitt Benckiser]].<ref>{{cite web |url=http://www.rb.com/site/RKBR/Templates/MediaInvestorsGeneral2.aspx?pageid=262&cc=GB |title=Announcements RB Press release - 10/12/2007 |access-date=16 November 2010 |archive-url=https://web.archive.org/web/20110715161154/http://www.rb.com/site/RKBR/Templates/MediaInvestorsGeneral2.aspx?pageid=262&cc=GB |archive-date=15 July 2011 |url-status=dead }}</ref><ref>{{cite news | vauthors = Goldstein J |title=FDA Bumps Phlegm-Fighters From Market |url=https://blogs.wsj.com/health/2007/05/25/fda-bumps-phlegm-fighters-from-market/ |date=25 May 2007 |newspaper=The Wall Street Journal |access-date=16 November 2010}}</ref> The drug is now sold over-the-counter by many companies, alone and in combination.<ref>{{Cite web|title=Guaifenesin (Oral Route) Description and Brand Names |url=https://www.mayoclinic.org/drugs-supplements/guaifenesin-oral-route/description/drg-20068720|access-date=27 July 2021|website=Mayo Clinic }}</ref>

==Veterinary use==
⚫
Guaifenesin's neurological properties first became known in the late 1940s. Guaifenesin is a centrally acting [[muscle relaxant]] used routinely in large-animal veterinary surgery. Guaifenesin is used in combination with, for example, [[ketamine]], since guaifenesin does not provide analgesia or produce unconsciousness.<ref>{{cite book |title=Lumb and Jones' Veterinary Anesthesia and Analgesia |date=2007 |publisher=Blackwell Publishing |veditors=Tranquilli WJ, Thurmon JC, Grimm KA |edition=2nd |chapter=Centrally Acting Muscle Relaxants}}</ref><ref name="horse">{{cite journal |vauthors=Valverde A |date=Apr 2013 |title=Balanced anesthesia and constant-rate infusions in horses |journal=Vet Clin North Am Equine Pract |volume=29 |issue=1 |pages=89–122 |doi=10.1016/j.cveq.2012.11.004 |pmid=23498047}}</ref> In horses, the drug's biological half-life is 77 minutes. Premedication with [[xylazine]] (1.1&nbsp;mg/kg) can reduce the dose required from 163&nbsp;mg/kg (in geldings) to just 88&nbsp;mg/kg.<ref name="horse" />


== Society and culture ==
== Society and culture ==

⚫
===Guaifenesin in fibromyalgia===
⚫
{{Main|Guaifenesin protocol}}
⚫
In the 1990s, Paul St. Amand, M.D., suggested guaifenesin as part of a fibromyalgia treatment protocol. Results of a one-year 1996 randomized clinical trial did not support the hypothesis. As of 2015, the FDA had not approved guaifenesin as a drug treatment for the disorder.<ref>{{cite web | url=https://www.ncbi.nlm.nih.gov/books/NBK274463/table/introduction.t1/ | title=Table 1, FDA-approved drugs for the treatment of fibromyalgia | date=January 2015 }}</ref> However, results of a 2017 multicenter, placebo-controlled, repeat-dose, parallel study of 77 randomly assigned adults, suggested potential for OTC dose of oral guaifenesin 1200 mg BID to provide symptomatic relief of upper back musculoskeletal pain and spasm.<ref>{{cite journal | vauthors = Collaku A, Yue Y, Reed K | title = Efficacy and safety of guaifenesin for upper back, neck, and shoulder pain: a Phase II proof-of-concept, multicenter, placebo-controlled, repeat-dose, parallel-group study | journal = Journal of Pain Research | volume = 10 | pages = 669–678 | date = 2017 | pmid = 28356767 | pmc = 5367561 | doi = 10.2147/JPR.S126296 | doi-access = free }}</ref>

=== Brand names ===
=== Brand names ===
Guaifenesin is [[Oral administration|taken by mouth]],<ref name=drugs/> and is supplied as a tablet, a capsule, an extended-release (long-acting) tablet, dissolving granules, and a syrup.<ref name=nlm/> It is available under many [[Drug nomenclature#Trade names|brand name]]s, as either the sole [[active ingredient]] or part of a [[combination drug]].<ref name=nlm/> Drugs combined with guaifenesin in over-the-counter preparations include the cough-suppressant [[dextromethorphan]], [[analgesics]] such as [[paracetamol]]/acetaminophen, and [[decongestants]] such as [[ephedrine]], [[pseudoephedrine]], or [[phenylephrine]].<ref name=nlm/>
Guaifenesin is [[Oral administration|taken by mouth]],<ref name=drugs/> and is supplied as a tablet, a capsule, an extended-release (long-acting) tablet, dissolving granules, and a syrup.<ref name=nlm/> It is available under many [[Drug nomenclature#Trade names|brand name]]s, as either the sole [[active ingredient]] or part of a [[combination drug]].<ref name=nlm/> Drugs combined with guaifenesin in over-the-counter preparations include the cough-suppressant [[dextromethorphan]], [[analgesics]] such as [[paracetamol]]/acetaminophen, and [[decongestants]] such as [[ephedrine]], [[pseudoephedrine]], or [[phenylephrine]].<ref name=nlm/>
Line 100: Line 95:
In 2014, sales of guaifenesin were estimated to be approximately $135 million per year in the United States.<ref name="pmid24789023" />
In 2014, sales of guaifenesin were estimated to be approximately $135 million per year in the United States.<ref name="pmid24789023" />


==Veterinary use==
==Research==
⚫
===Guaifenesin in fibromyalgia===
⚫
Guaifenesin's neurological properties first became known in the late 1940s. Guaifenesin is a centrally acting [[muscle relaxant]] used routinely in large-animal veterinary surgery. Guaifenesin is used in combination with, for example, [[ketamine]], since guaifenesin does not provide analgesia or produce unconsciousness.<ref>{{cite book | veditors = Tranquilli WJ, Thurmon JC, Grimm KA | date = 2007 | edition = 2nd | title = Lumb and Jones' Veterinary Anesthesia and Analgesia | publisher = Blackwell Publishing | chapter = Centrally Acting Muscle Relaxants }}</ref><ref name=horse>{{cite journal | vauthors = Valverde A | date = Apr 2013 | title = Balanced anesthesia and constant-rate infusions in horses | journal = Vet Clin North Am Equine Pract | volume = 29 | issue = 1| pages = 89–122 | doi = 10.1016/j.cveq.2012.11.004 | pmid = 23498047 }}</ref> In horses, the drug's biological half-life is 77 minutes. Premedication with [[xylazine]] (1.1&nbsp;mg/kg) can reduce the dose required from 163&nbsp;mg/kg (in geldings) to just 88&nbsp;mg/kg.<ref name=horse/>
⚫
{{Main|Guaifenesin protocol}}
⚫
In the 1990s, Paul St. Amand, M.D., suggested guaifenesin as part of a [[fibromyalgia]] treatment protocol. The results of a one-year 1996 randomized clinical trial did not support the hypothesis. As of 2015, the FDA had not approved guaifenesin as a drug treatment for the disorder.<ref>{{cite web | url=https://www.ncbi.nlm.nih.gov/books/NBK274463/table/introduction.t1/ | title=Table 1, FDA-approved drugs for the treatment of fibromyalgia | date=January 2015 }}</ref> However, results of a 2017 multicenter, placebo-controlled, repeat-dose, parallel study of 77 randomly assigned adults, suggested potential for OTC dose of oral guaifenesin 1200 mg BID to provide symptomatic relief of upper back musculoskeletal pain and spasm.<ref>{{cite journal | vauthors = Collaku A, Yue Y, Reed K | title = Efficacy and safety of guaifenesin for upper back, neck, and shoulder pain: a Phase II proof-of-concept, multicenter, placebo-controlled, repeat-dose, parallel-group study | journal = Journal of Pain Research | volume = 10 | pages = 669–678 | date = 2017 | pmid = 28356767 | pmc = 5367561 | doi = 10.2147/JPR.S126296 | doi-access = free }}</ref>


==See also==
==See also==

Revision as of 13:04, 15 December 2024

Guaifenesin
Clinical data
Pronunciation/ɡwaɪˈfɛnɪsɪn/[1]
Trade namesMucinex, others
Other namesGlyceryl guaiacolate
AHFS/Drugs.comMonograph
MedlinePlusa682494
License data
Routes of
administration		By mouth
Drug classExpectorant
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismKidney
Elimination half-life1–5 hours[3]
Identifiers
  • (RS)-3-(2-methoxyphenoxy)propane-1,2-diol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.002.021 Edit this at Wikidata
Chemical and physical data
FormulaC10H14O4
Molar mass198.218 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O(c1ccccc1OC)CC(O)CO
  • InChI=1S/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3 checkY
  • Key:HSRJKNPTNIJEKV-UHFFFAOYSA-N checkY
  (verify)

Guaifenesin, also known as glyceryl guaiacolate, is an expectorant medication taken by mouth and marketed as an aid to eliminate sputum from the respiratory tract. Chemically, it is an ether of guaiacol and glycerine. It may be used in combination with other medications.[4] A 2014 study found that guaifenesin does not affect sputum volume in upper respiratory infections (the upper respiratory system includes most breathing parts above the lungs).[5][6]

Side effects may include dizziness, sleepiness, skin rash, and nausea.[4] While it has not been properly studied in pregnancy, it appears to be safe.[7] It is believed to work by making airway secretions more liquid.[4]

Guaifenesin has been used medically since at least 1933.[8] It is available as a generic medication and over-the-counter (OTC).[4][7] In 2021, it was the 288th most commonly prescribed medication in the United States, with more than 600,000 prescriptions.[9][10]

Medical uses

Guaifenesin is used to try to help with coughing up thick mucus. It is sometimes combined with the antitussive (cough suppressant) dextromethorphan, such as in Mucinex DM or Robitussin DM.[11] It is also combined with ephedrine in Primatene and Bronkaid tablets for symptomatic relief of asthma. Guaifenesin is combined with phenylephrine and paracetamol in certain Lemsip formulations.[12]

A Cochrane review identified three clinical trials assessing guaifenesin for the treatment of acute cough, with one finding significant benefit and the other two trials finding that it was not effective.[13]

Side effects

Although generally well-tolerated, side effects of guaifenesin may include an allergic reaction (rare), nausea, vomiting, dizziness, or headache.[14][15]

Pharmacology

Mechanism of action

Guaifenesin might act as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi via stimulation of the gastric mucosa. This stimulation leads to an increased parasympathetic activity in the respiratory tract via the so-called gastro-pulmonary reflex, although some in vitro studies suggested that it might also act directly on the respiratory epithelium.[16] This increase in volume and reduction in viscosity aids in the flow of respiratory tract secretions, allowing ciliary movement to carry the loosened secretions upward toward the pharynx.[17][18]Thus, guaifenesin may increase the efficiency of the cough reflex and facilitate the removal of the secretions. Additionally, guaifenesin has a demonstrated central antitussive effect.[19]

History

Similar medicines derived from the guaiac tree were used as a generic remedy by American indigenous peoples when explorers reached North America in the 16th century. The Spanish encountered guaiacum wood "when they conquered Santo Domingo; it was soon brought back to Europe, where it acquired an immense reputation in the sixteenth century as a cure for syphilis and certain other diseases..."[20]

The 1955 edition of the Textbook of Pharmacognosy states: "Guaiacum has a local stimulant action which is sometimes useful in sore throat. The resin is used in chronic gout and rheumatism, whilst the wood is an ingredient in the compound concentrated solution of sarsaparilla, which was formerly much used as an alternative in syphilis."[20]

In the US, guaifenesin was first approved by the Food and Drug Administration (FDA) in 1952. Although previously deemed "Generally Regarded as Safe" in its original approval, the drug received a New Drug Application for the extended-release version, which received approval on 12 July 2002.[21] Because of this, the FDA then issued letters to other manufacturers of timed-release guaifenesin to stop marketing their unapproved versions, leaving Adams Respiratory Therapeutics in control of the market. In 2007, Adams was acquired by Reckitt Benckiser.[22][23] The drug is now sold over-the-counter by many companies, alone and in combination.[24]

Veterinary use

Guaifenesin's neurological properties first became known in the late 1940s. Guaifenesin is a centrally acting muscle relaxant used routinely in large-animal veterinary surgery. Guaifenesin is used in combination with, for example, ketamine, since guaifenesin does not provide analgesia or produce unconsciousness.[25][26] In horses, the drug's biological half-life is 77 minutes. Premedication with xylazine (1.1 mg/kg) can reduce the dose required from 163 mg/kg (in geldings) to just 88 mg/kg.[26]

Society and culture

Brand names

Guaifenesin is taken by mouth,[4] and is supplied as a tablet, a capsule, an extended-release (long-acting) tablet, dissolving granules, and a syrup.[15] It is available under many brand names, as either the sole active ingredient or part of a combination drug.[15] Drugs combined with guaifenesin in over-the-counter preparations include the cough-suppressant dextromethorphan, analgesics such as paracetamol/acetaminophen, and decongestants such as ephedrine, pseudoephedrine, or phenylephrine.[15]

Economics

In 2014, sales of guaifenesin were estimated to be approximately $135 million per year in the United States.[6]

Research

Guaifenesin in fibromyalgia

Main article: Guaifenesin protocol

In the 1990s, Paul St. Amand, M.D., suggested guaifenesin as part of a fibromyalgia treatment protocol. The results of a one-year 1996 randomized clinical trial did not support the hypothesis. As of 2015, the FDA had not approved guaifenesin as a drug treatment for the disorder.[27] However, results of a 2017 multicenter, placebo-controlled, repeat-dose, parallel study of 77 randomly assigned adults, suggested potential for OTC dose of oral guaifenesin 1200 mg BID to provide symptomatic relief of upper back musculoskeletal pain and spasm.[28]

See also

References

  1. ^ "Guaifenesin Definition & Meaning". Merriam-Webster.
  2. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  3. ^ Aluri JB, Stavchansky S (1993). "Determination of guaifenesin in human plasma by liquid chromatography in the presence of pseudoephedrine". J Pharm Biomed Anal. 11 (9): 803–808. doi:10.1016/0731-7085(93)80072-9. PMID 8218524.
  4. ^ a b c d e "Guaifenesin: Monograph for Professionals". Drugs.com, American Society of Health-System Pharmacists. 23 January 2023. Retrieved 30 July 2023.
  5. ^ Hoffer-Schaefer A, Rozycki HJ, Yopp MA, Rubin BK (May 2014). "Guaifenesin has no effect on sputum volume or sputum properties in adolescents and adults with acute respiratory tract infections". Respiratory Care. 59 (5): 631–636. doi:10.4187/respcare.02640. PMID 24003241.
  6. ^ a b O'Connell OJ (May 2014). "Is extended-release guaifenesin no better than a placebo?". Respir Care. 59 (5): 788–9. doi:10.4187/respcare.03319. PMID 24789023.
  7. ^ a b Weiner CP, Rope K (2013). The Complete Guide to Medications During Pregnancy and Breastfeeding: Everything You Need to Know to Make the Best Choices for You and Your Baby. St. Martin's Press. p. PT282. ISBN 9781250037206.
  8. ^ Riviere JE, Papich MG (2013). Veterinary Pharmacology and Therapeutics. John Wiley & Sons. p. 287. ISBN 9781118685907.
  9. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  10. ^ "Guaifenesin – Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  11. ^ "Guaifenesin DM". WebMD.com.
  12. ^ "Lemsip Max All in One". LemsipUK. Retrieved 4 November 2024.
  13. ^ Smith SM, Schroeder K, Fahey T (November 2014). "Over-the-counter (OTC) medications for acute cough in children and adults in community settings". Cochrane Database Syst Rev. 2014 (11): CD001831. doi:10.1002/14651858.CD001831.pub5. PMC 7061814. PMID 25420096.
  14. ^ "Guaifenesin Side Effects". Drugs.com. 3 July 2023. Retrieved 30 July 2023.
  15. ^ a b c d "Guaifenesin". MedlinePlus, United States National Library of Medicine. 15 January 2022. Retrieved 30 July 2023.
  16. ^ Albrecht HH, Dicpinigaitis PV, Guenin EP (11 December 2017). "Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections". Multidisciplinary Respiratory Medicine. 12 (1): 31. doi:10.1186/s40248-017-0113-4. PMC 5724298. PMID 29238574.
  17. ^ Gutierrez K (2007). Pharmacotherapeutics: clinical reasoning in primary care. St. Louis, Mo: Saunders Elsevier. ISBN 978-1-4160-3287-8.
  18. ^ Ohar JA, Donohue JF, Spangenthal S (October 2019). "The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review". Chronic Obstructive Pulmonary Diseases. 6 (4): 341–349. PMID 31647856.
  19. ^ Ohar JA, Donohue JF, Spangenthal S (October 2019). "The Role of Guaifenesin in the Management of Chronic Mucus Hypersecretion Associated with Stable Chronic Bronchitis: A Comprehensive Review". Chronic Obstructive Pulmonary Diseases. 6 (4): 341–349. PMID 31647856.
  20. ^ a b Wallis TE (1955). Textbook of Pharmacognosy.
  21. ^ "Drug Approval Package: Mucinex (Guaifenesin) NDA #21-282". accessdata.fda.gov. 25 November 2002. Retrieved 26 October 2022.
  22. ^ "Announcements RB Press release - 10/12/2007". Archived from the original on 15 July 2011. Retrieved 16 November 2010.
  23. ^ Goldstein J (25 May 2007). "FDA Bumps Phlegm-Fighters From Market". The Wall Street Journal. Retrieved 16 November 2010.
  24. ^ "Guaifenesin (Oral Route) Description and Brand Names". Mayo Clinic. Retrieved 27 July 2021.
  25. ^ Tranquilli WJ, Thurmon JC, Grimm KA, eds. (2007). "Centrally Acting Muscle Relaxants". Lumb and Jones' Veterinary Anesthesia and Analgesia (2nd ed.). Blackwell Publishing.
  26. ^ a b Valverde A (April 2013). "Balanced anesthesia and constant-rate infusions in horses". Vet Clin North Am Equine Pract. 29 (1): 89–122. doi:10.1016/j.cveq.2012.11.004. PMID 23498047.
  27. ^ "Table 1, FDA-approved drugs for the treatment of fibromyalgia". January 2015.
  28. ^ Collaku A, Yue Y, Reed K (2017). "Efficacy and safety of guaifenesin for upper back, neck, and shoulder pain: a Phase II proof-of-concept, multicenter, placebo-controlled, repeat-dose, parallel-group study". Journal of Pain Research. 10: 669–678. doi:10.2147/JPR.S126296. PMC 5367561. PMID 28356767.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Guaifenesin&oldid=1263228716"